Annovis Bio upgraded by Maxim Group with a new price target
$ANVS
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/25/2024 | $25.00 | Hold → Buy | Maxim Group |
| 12/29/2023 | $36.00 | Buy | Canaccord Genuity |
| 7/7/2021 | $45.00 → $150.00 | Buy | Maxim Group |
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap.In 2016, the Company filed a patent covering the treatment of various nerve insults, including TBI, stroke, and nerve and spinal cord injuries. While these claims were granted in Europe and worldwide, the U.S. Patent and Trademark Office (USPTO) required the claims to be divided into individual patents for each indic
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $30 price target.
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct
LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE:ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurode
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer's Disease (CTAD) conference. The event will be held from October 29 to November 1, 2024, in Madrid, Spain. Dr. Maria Maccecchini, President and CEO of Annovis Bio, will present the following posters: Poster LP023 Title: Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer's Patients. Date: Tuesd
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD patients. Annovis and the FDA have now aligned on a development path for buntanetap towar
Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00
Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00
Maxim Group reiterated coverage of Annovis Bio with a rating of Buy and set a new price target of $150.00 from $45.00 previously
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)
SC 13G - Annovis Bio, Inc. (0001477845) (Subject)
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a
TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres
BERWYN, Penn., Nov. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments. Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: "This quarter, we have made significant advances in the clinical development of buntanetap as we began to dose patients in our Phase 3 trial for early Parkinson's Disease and received FDA author